From the article.
“Medicare still doesn’t cover drugs for obesity, but a recent article in the New England Journal of Medicine warned that, in the hypothetical scenario that all Medicare beneficiaries with obesity were to use Wegovy, the cost would exceed the entire Medicare Part D budget. And if just 10% of obese people on Medicare were to take it at the net annual price of about $13,600, it would cost Medicare nearly $27 billion a year, according to the study. Unless the list price of Wegovy were discounted by more than 40%, the overall cost of the medication would eclipse the benefits to the U.S. healthcare system of lower obesity levels, according to a report by the Institute for Clinical and Economic Review.”
Share this post